This study aimed to evaluate associations between commonly used antidiabetic regimens and the incidence of three cognitive outcomes—mild cognitive disorder, Alzheimer disease, and vascular dementia—in adults with type 2 diabetes.
The investigation was a retrospective cohort analysis using the TriNetX US Collaborative Network of electronic health records covering 2010 through 2024. Included were adults aged 40 to 69 years with a diagnosis of type 2 diabetes and at least one year of follow-up. The full cohort comprised 1,528,885 individuals. The mean age reported for the cohort was 58 years, and 49.2% were women. Propensity score matching was applied to balance covariates between treatment groups; the abstract does not enumerate the specific baseline covariates included in the propensity model.
Patients were categorized according to initial recorded prescription and continued use during follow-up into five mutually exclusive exposure groups:
Exposure classification was based on the first recorded prescription and continued use, as noted in the source. The abstract does not provide detailed timing of drug initiation relative to diabetes duration or glycemic control metrics at baseline.
Primary outcomes were incident diagnoses of mild cognitive disorder, Alzheimer disease, and vascular dementia as identified by ICD-10 diagnostic codes in the electronic health record. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazards models. The investigators also performed landmark analyses to assess associations for follow-up shorter than 5 years and for follow-up longer than 5 years. The abstract does not provide absolute incidence rates, event counts for each exposure group, or the full list of covariates included in the Cox models.
Across the cohort of 1,528,885 adults with type 2 diabetes, treatment-specific associations with incident cognitive disorders were reported relative to metformin monotherapy:
Metformin plus GLP-1 receptor agonists was associated with reduced incidence of vascular dementia (HR, 0.46; 95% CI, 0.37–0.57), reduced incidence of mild cognitive disorder (HR, 0.79; 95% CI, 0.66–0.95), and reduced incidence of Alzheimer disease (HR, 0.46; 95% CI, 0.31–0.70).
Metformin plus SGLT-2 inhibitors was associated with a lower risk of vascular dementia (HR, 0.68; 95% CI, 0.54–0.87) but was not reported as significantly associated with reductions in mild cognitive disorder or Alzheimer disease in the abstract.
Insulin monotherapy was associated with higher incidence across outcomes: vascular dementia (HR, 3.27; 95% CI, 3.03–3.52), mild cognitive disorder (HR, 1.71; 95% CI, 1.56–1.87), and Alzheimer disease (HR, 1.56; 95% CI, 1.32–1.84).
The results reported are associations derived from adjusted survival models; the abstract does not present absolute risks, numbers needed to treat or harm, or time-to-event curves in the text.
In this large retrospective cohort of adults with type 2 diabetes, combinations of metformin with GLP-1 receptor agonists or with SGLT-2 inhibitors were associated with a lower risk of certain cognitive outcomes—most notably a reduced incidence of vascular dementia. By contrast, insulin monotherapy was associated with substantially higher hazard ratios for vascular dementia, mild cognitive disorder, and Alzheimer disease compared with metformin monotherapy. The authors summarize these findings as associations between antidiabetic regimen and subsequent diagnosis of cognitive disorders.
The abstract reports study design, cohort size, exposure groups, outcomes, and modeled hazard ratios with 95% CIs, but several methodological and contextual details are not provided in the abstract text and therefore were not reported in the source excerpt. These unreported details include:
Because the source provided is the article abstract only, additional methodological and numerical detail would require consulting the full article.